TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis.

Anna StengelClaudia Haferlach


TP53 is the most extensively studied gene in cancer. However, data on frequency and the prognostic impact of TP53 mutations in acute lymphoblastic leukemia (ALL) remain scarce. Thus, we aimed at identifying the mutation frequency of TP53, its association with cytogenetic subgroups, and its impact on survival in a large cohort of 625 patients with ALL. Our data revealed an overall mutation incidence of 15.7%, which increases with age. Correlation with cytogenetic subgroups showed that mutations were most frequent in ALL with low hypodiploidy or MYC-rearrangements. Furthermore, for a large number of patients, both TP53 alleles were altered, either by 2 TP53 mutations (12%) or by a TP53 mutation and a TP53 deletion in the second allele (39%). A high TP53 mutation load was correlated to low hypodiploidy, high hyperdiploidy, and a complex karyotype. Moreover, a higher mutation load was found in B-lineage ALL compared with T-lineage ALL. Similar to other cancers, the median overall survival was significantly shorter in patients with TP53 mutation compared with patients with wild-type TP53. This effect was especially pronounced when both TP53 alleles were affected, either by 2 TP53 mutations or by both a mutation and an accompanying T...Continue Reading


Feb 1, 1992·British Journal of Haematology·P FenauxJ P Kerckaert
Jul 2, 1992·Nature·D P Lane
Apr 1, 1995·Nature Structural Biology·G M CloreA M Gronenborn
Apr 1, 1994·International Journal of Cancer. Journal International Du Cancer·T SoussiB Schlichtholz
Jun 20, 1998·Human Mutation·M ProkocimerG Rennert
Aug 27, 1998·The New England Journal of Medicine·C H Pui, W E Evans
Sep 23, 1998·Genes & Development·K SakaguchiE Appella
May 26, 1999·The Journal of Pathology·D Wynford-Thomas
Nov 5, 1999·Advances in Cancer Research·P Hainaut, M Hollstein
Mar 20, 2002·Nature Reviews. Cancer·A N Bullock, A R Fersht
Aug 7, 2002·Current Oncology Reports·Claudia Schoch, Torsten Haferlach
Nov 26, 2003·Molecular Carcinogenesis·Xabier AgirreJosé L Vizmanos
Mar 25, 2008·Lancet·Ching-Hon PuiA Thomas Look
May 20, 2009·Cell·Jan-Philipp Kruse, Wei Gu
Aug 11, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thorsten ZenzStephan Stilgenbauer
Jul 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jana HofRenate Kirschner-Schwabe
Dec 13, 2012·Hematology·Charles G Mullighan
Jan 22, 2013·Nature Genetics·Linda HolmfeldtCharles G Mullighan
Mar 12, 2013·Current Hematologic Malignancy Reports·A K Fielding, G A Zakout
May 18, 2013·The Journal of Molecular Diagnostics : JMD·Vera GrossmannAlexander Kohlmann

❮ Previous
Next ❯


Jan 28, 2016·Nature Genetics·Peter UlzMichael R Speicher
May 29, 2015·British Journal of Haematology·Maxwell M KremTimothy Tidwell
Jul 3, 2015·Molecular Cytogenetics·Moneeb A K OthmanThomas Liehr
Jul 12, 2014·Blood·Anthony V Moorman
Jun 22, 2016·Experimental Hematology·Kensuke KojimaMichael Andreeff
Aug 10, 2016·Current Hematologic Malignancy Reports·Lynda M Vrooman, Lewis B Silverman
Nov 5, 2016·Cancer Genetics·Sabine HaberlClaudia Haferlach
May 31, 2017·British Journal of Cancer·Maribel Forero-CastroJesús-María Hernández-Rivas
Jul 7, 2017·Leukemia & Lymphoma·Silvia SalmoiraghiOrietta Spinelli
Feb 15, 2019·Journal of Oncology Practice·Ibrahim AldossVinod Pullarkat
Dec 20, 2017·Drugs & Aging·Nicola Gökbuget
May 16, 2019·Journal of Cellular Biochemistry·Manjima ChatterjeeSonali Sengupta
Nov 14, 2019·Cancers·Andrea Ghelli Luserna Di RoràGiovanni Martinelli
Apr 6, 2019·Current Drug Targets·Maryam Zanjirband, Soheila Rahgozar
Oct 5, 2015·Current Hematologic Malignancy Reports·Nathanael G Bailey, Kojo S J Elenitoba-Johnson
Jan 8, 2019·Annals of Hematology·Jan A StratmannBjörn Steffen
Jun 2, 2018·Journal of Hematology & Oncology·Enrico DerenziniDavide Treré
Dec 27, 2016·Frontiers in Pharmacology·Stefania TrinoPellegrino Musto
Dec 4, 2016·Hematology·Nicola Gökbuget
Nov 16, 2019·Cancer Science·Chih-Hsiang YuYung-Li Yang
Jul 28, 2016·Cold Spring Harbor Perspectives in Medicine·Ana I RoblesCurtis C Harris
Jun 23, 2019·Molecular Cancer Therapeutics·Sankaranarayanan KannanPatrick A Zweidler-McKay
Mar 14, 2019·Cancer Research·Ernesto Diaz-FloresMignon L Loh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.